Shopping Cart
Remove All
Your shopping cart is currently empty
W146 is a selective and potent Sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist that induces significant but transient hematolymphopenia in mice.W146 induces significant but transient hematolymphopenia in mice, inducing pulmonary edema.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | - | In Stock | |
| 5 mg | $455 | - | In Stock | |
| 10 mg | $787 | - | In Stock | |
| 25 mg | $1,570 | - | In Stock | |
| 50 mg | $2,520 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | Inquiry | - | In Stock |
| Description | W146 is a selective and potent Sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist that induces significant but transient hematolymphopenia in mice.W146 induces significant but transient hematolymphopenia in mice, inducing pulmonary edema. |
| Targets&IC50 | S1P1 receptor:70-80 nM(Ki) |
| In vitro | W146 is an antagonist of S1PR1 (Ki: 70-80 nM). [1] W146 pretreatment significantly increased the TUNEL labeling index of endothelial progenitor cells (EPCs) compared with the S1P-treated group. W146 pretreatment significantly increased the level of activated cleaved caspase-3. S1P was able to reduce apoptosis in EPCs, but this protective effect was completely lost after W146 treatment. [2] |
| In vivo | In mice, Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count. when mice are pretreated with W146, it is found that a significant increase in KSL-HSPC mobilization, compared to that in mice pretreated with dextran followed by AMD3100 administration. Moreover, pre-treatment of W146 shows an approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony-forming assays, compared to that in mice treated with AMD3100 alone. [3] |
| Synonyms | W-146, W 146 |
| Molecular Weight | 342.37 |
| Formula | C16H27N2O4P |
| Cas No. | 909725-61-7 |
| Smiles | N(C([C@@H](CCP(=O)(O)O)N)=O)C1=CC(CCCCCC)=CC=C1 |
| Relative Density. | 1.233 g/cm3 (Predicted) |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 15 mg/mL (43.81 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.